Ampio Pharmaceuticals, Inc. Press Releases

AMPE 
$3.41
*  
0.11
3.12%
Get AMPE Alerts
*Delayed - data as of Nov. 25, 2014  -  Find a broker to begin trading AMPE now
Exchange: AMEX
Industry: Health Care
Community Rating:
View:    AMPE Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress
11/24/2014 8:00:00 AM - PR Newswire


Ampio updates status of clinical trials and manufacturing facility
11/12/2014 8:00:00 AM - PR Newswire
▼-6.06 % Price Change since this news event. The Volume Ratio is 4.46.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences
10/20/2014 8:00:00 AM - PR Newswire
▼-18.03 % Price Change since this news event. The Volume Ratio is 0.58.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial
10/16/2014 4:02:00 PM - PR Newswire
▼-14.75 % Price Change since this news event. The Volume Ratio is 2.22.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting
9/15/2014 2:00:00 PM - PR Newswire


Update on the Phase III multicenter, double-blind STEP study of Ampion™ for Osteoarthritis of the Knee
9/2/2014 7:56:00 AM - PR Newswire